Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influenza humana - antivirais para uso sistêmico - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agentes antineoplásicos - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - carcinoma, célula basal - agentes antineoplásicos - erivedge é indicado para o tratamento de pacientes adultos com:- sintomático de uma metástase de carcinoma basocelular - localmente avançados de carcinoma basocelular inapropriadas para a cirurgia ou radioterapia.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - atrofia muscular, espinhal - outras drogas para distúrbios do sistema músculo-esquelético - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunossupressores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imune soros e imunoglobulinas, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. veja as seções 4. 4 e 5.

Uniunea Europeană - portugheză - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmológicos - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Portugalia - portugheză - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ptr pharma consulting, lda - ceftriaxona - pó e solvente para solução injetável - 1000 mg/10 ml - ceftriaxona sódica 1193 mg - ceftriaxone - genérico - duração do tratamento: curta ou média duração

Portugalia - portugheză - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ptr pharma consulting, lda - ceftriaxona - pó e solvente para solução injetável - 500 mg/5 ml - ceftriaxona sódica 596.5 mg - ceftriaxone - genérico - duração do tratamento: curta ou média duração